NB
NBIX.US Neurocrine Biosciences Inc
- Market cap
- USD 16.7B
- P/E
- 24.8x
- P/B
- 4.37x
- ROE
- 18.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is NBIX.US undervalued?
Graham numberNBIX.US trades 119.5% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Neurocrine Biosciences Inc fundamental analysis
No fundamental analysis for Neurocrine Biosciences Inc yet.
Neurocrine Biosciences Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under th…
Full company profileNeurocrine Biosciences Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Neurocrine Biosciences Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 15.0M | 162M | 451M | 788M | 1.05B | 1.13B | 1.49B | 1.89B | 2.36B | 2.86B | 3.86B |
| Gross Profit | 15.0M | 160M | 446M | 781M | 1.04B | 1.12B | 1.47B | 1.85B | 2.32B | 2.81B | 3.78B |
| Operating Income | -147M | -131M | 36.9M | 72.3M | 163M | 103M | 249M | 251M | 571M | 619M | 894M |
| EBITDA | -140M | -121M | 40.9M | 85.9M | 148M | 138M | 265M | 416M | 640M | 667M | 948M |
| Net Income | -141M | -143M | 21.1M | 37.0M | 407M | 89.6M | 155M | 250M | 341M | 479M | 732M |
| EPS | -1.63 | -1.62 | 0.22 | 0.39 | 4.16 | 0.92 | 1.56 | 2.47 | 3.29 | 4.67 | 6.96 |
| Balance Sheet | |||||||||||
| Total Assets | 365M | 818M | 993M | 1.31B | 1.73B | 2.07B | 2.37B | 3.25B | 3.72B | 4.63B | 5.63B |
| Total Liabilities | 50.2M | 445M | 512M | 669M | 609M | 699M | 661M | 1.02B | 1.13B | 1.38B | 1.75B |
| Shareholders' Equity | 315M | 372M | 481M | 637M | 1.13B | 1.37B | 1.71B | 2.23B | 2.59B | 3.25B | 3.88B |
| Cash & Short-term Investments | 307M | 516M | 651M | 671M | 801M | 711M | 989M | 1.03B | 1.08B | 1.48B | 738M |
| Total Debt | - | 408M | 451M | 818M | 412M | 440M | 263M | 428M | 455M | 415M | 392M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -106M | -94.3M | 101M | 147M | 229M | 257M | 339M | 390M | 595M | 783M | 903M |
| Capital Expenditure | 4.11M | 6.94M | 24.8M | 14.7M | 10.9M | 23.4M | 16.5M | 28.3M | 38.2M | 34.0M | 38.0M |
| Free Cash Flow | -110M | -101M | 76.6M | 132M | 218M | 233M | 323M | 362M | 557M | 749M | 865M |
| Ratios | |||||||||||
| ROE | -44.8% | -38.3% | 4.4% | 5.8% | 36.2% | 6.5% | 9.0% | 11.2% | 13.2% | 14.7% | 18.9% |
| ROA | -38.6% | -17.4% | 2.1% | 2.8% | 23.5% | 4.3% | 6.5% | 7.7% | 9.2% | 10.3% | 13.0% |
| Net Profit Margin | -940.6% | -88.2% | 4.7% | 4.7% | 38.9% | 7.9% | 10.4% | 13.2% | 14.5% | 16.7% | 18.9% |
| Debt to Equity | - | 1.10x | 0.94x | 1.28x | 0.37x | 0.32x | 0.15x | 0.19x | 0.18x | 0.13x | 0.10x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Neurocrine Biosciences Inc dividends
Neurocrine Biosciences Inc has not paid dividends in the last 9 fiscal years.
Who owns Neurocrine Biosciences Inc
- Insiders 1.56%
- Institutions 98.44%
- Public & others 0.00%
- Shares outstanding 101M
- Free float 99.9M
Top funds holding NBIX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Dodge & Cox Stock I | 3.91M | 3.86% | -1.47% | Sep 2026 |
| iShares Core S&P Mid-Cap ETF | 3.65M | 3.61% | +0.05% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 3.23M | 3.20% | +1.10% | Sep 2026 |
| Vanguard Small Cap Index | 2.29M | 2.26% | -1.10% | Sep 2026 |
| Vanguard MStar Small Cap Growth Indx Inv | 1.27M | 1.26% | -4.15% | Sep 2026 |
| State Street® SPDR® S&P® Biotech ETF | 1.02M | 1.01% | +2.68% | Oct 2026 |
| JPMorgan Mid Cap Growth I | 903K | 0.89% | -1.57% | Sep 2026 |
| JPMorgan Growth Advantage A | 806K | 0.80% | -2.20% | Sep 2026 |
| iShares Biotechnology ETF | 782K | 0.77% | -0.32% | Oct 2026 |
| State Street® SPDR® S&P MIDCAP 400® ETF | 752K | 0.74% | +2.21% | Sep 2026 |
| VictoryShares Free Cash Flow ETF | 750K | 0.74% | +0.34% | Oct 2026 |
| First Trust NYSE Arca Biotech ETF | 687K | 0.68% | 0.00% | Oct 2026 |
| iShares MSCI USA Min Vol Factor ETF | 679K | 0.67% | +0.26% | Oct 2026 |
| Invesco S&P MidCap Quality ETF | 673K | 0.66% | +0.14% | Oct 2026 |
| Vanguard Explorer Inv | 641K | 0.63% | +0.48% | Sep 2026 |
| iShares S&P Mid-Cap 400 Growth ETF | 612K | 0.60% | -0.26% | Oct 2026 |
| State Street SPDR Port S&P 400 Md CpETF | 553K | 0.55% | 0.00% | Oct 2026 |
| iShares Russell Mid-Cap Growth ETF | 480K | 0.47% | -0.07% | Oct 2026 |
| Fidelity Extended Market Index | 466K | 0.46% | -4.77% | Sep 2026 |
| Vanguard Capital Opportunity Inv | 421K | 0.42% | +1.20% | Sep 2026 |
Top institutions holding NBIX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 13.7M | 13.55% | +2.44% | Jun 2026 |
| JPMorgan Chase & Co | 6.40M | 6.32% | +17.58% | Jun 2026 |
| Dodge & Cox | 5.58M | 5.52% | +2.26% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 4.97M | 4.91% | +5.24% | Jun 2026 |
| Vanguard Capital Management, LLC | 4.55M | 4.49% | +0.74% | Jun 2026 |
| State Street Corp | 4.39M | 4.33% | +0.71% | Jun 2026 |
| AQR Capital Management LLC | 3.82M | 3.77% | -22.70% | Jun 2026 |
| Renaissance Technologies Corp | 2.30M | 2.27% | -1.51% | Sep 2026 |
| Geode Capital Management, LLC | 2.14M | 2.11% | +0.10% | Jun 2026 |
| Two Sigma Investments LLC | 2.08M | 2.05% | -32.16% | Jun 2026 |
| Vestal Point Capital LP | 1.88M | 1.86% | +50.40% | Jun 2026 |
| BNP Paribas Investment Partners SA | 1.49M | 1.48% | +0.03% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 1.32M | 1.30% | +8.15% | Jun 2026 |
| RTW INVESTMENTS, LLC | 1.27M | 1.25% | +19.38% | Jun 2026 |
| Northern Trust Corp | 1.26M | 1.24% | +1.36% | Jun 2026 |
| Amvescap Plc. | 1.08M | 1.06% | +202.61% | Jun 2026 |
| Charles Schwab Investment Management Inc | 974K | 0.96% | +7.92% | Jun 2026 |
| NORGES BANK | 974K | 0.96% | -15.09% | Jun 2026 |
| First Trust Advisors L.P. | 923K | 0.91% | -3.76% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 785K | 0.78% | +7.05% | Sep 2026 |
Neurocrine Biosciences Inc company profile
- Company name
- Neurocrine Biosciences Inc
- Ticker
- NBIX.US
- Exchange
- USA Stocks
- Listed since
- May 23, 1996
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2,500
- Fiscal year end
- December
- Address
- 6027 Edgewood Bend Court, San Diego, CA, United States, 92130
- Phone
- 858 617 7600
- Website
- neurocrine.com
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
Neurocrine Biosciences Inc management
10- Mr. Kyle W. Gano Ph.D.President, CEO & Director · born 1973
- Mr. Matthew C. Abernethy CPAChief Financial Officer · born 1980
- Dr. Jude Onyia Ph.D.Chief Scientific Officer · born 1964
- Mr. Eric S. BenevichChief Commercial Officer · born 1965
- Dr. Eiry Wyn Roberts M.D.Chief Medical Officer · born 1964
- Dr. Wylie W. Vale Ph.D.Co-Founder · born 1942
- Dr. Lawrence Steinman BA, M.D., Ph.D.Co-Founder of Neurocrine · born 1948
- Mr. Aaron VosburghSenior Vice President of Finance & Accounting
- Mr. Lewis ChoiChief Information Officer
- Mr. Todd TushlaVice President of Investor Relations